Articles related to STOMACH CANCER

The field of gastric and esophageal cancer treatment is witnessing remarkable advancements through targeted therapies and immunotherapies. Explore the latest clinical trials and discoveries that are redefining the standard of care for these traditionally difficult-to-treat cancers.

According to a new review, eating mushrooms may lower your risk of developing stomach cancer, and the benefits may be due to the fungi’s useful characteristics. To determine the connection between mushroom consumption and gastric cancer risk, the review examined the findings of a meta-analysis of previously published studies and the Stomach Cancer Pooling (StoP) Project. It was discovered that “higher mushroom consumption was associated with a lower risk of gastric cancer.” Eleven studies totaling 3,900 cases of stomach cancer and 7,792 control cases made up the StoP Project. Through questionnaires about food consumption, the mushrooms of study participants were assessed. Participants who consumed the most mushrooms compared to those who ate the fewest mushrooms had a relative risk (RR) of gastric cancer of 0.82. The researchers present a plausable analysis, but more research is needed to confirm if eating mushrooms truly reduces gastric cancer risks and, if so, why.

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

Neo-adjuvant therapy with nivolumab and ipilimumab is associated with a high pCR rate in ptsd with MSI/dMMR resectable OGA.